Search Results

Practical measures Schizophrenia and related psychoses CHAPTER 1 positive or negative effects and while adding a benzodiazepine to another drug may not be clearly advantageous it may lead to unnecessary adverse effects.49 With respect to those who are behaviou...

Zuclopenthixol acetate 66 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 Zuclopenthixol acetate Zuclopenthixol acetate (ZA) is widely used in the UK and elsewhere in Europe, and is best known by its trade name Acuphase®. Zuclopenthixol itself is ...

References Schizophrenia and related psychoses CHAPTER 1 References Patel MX, et al. Joint BAP NAPICU evidence-­based consensus guidelines for the clinical management of acute disturbance: de-­escalation and rapid tranquillisation. J Psychopharmacol 2018; 32:...

Antipsychotic depots/long-acting injections 74 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 Antipsychotic depots/long-­acting injections Long-­acting injectable preparations of antipsychotic medication are commonly prescribed in clinical practi...

Advice on prescribing LAIs Schizophrenia and related psychoses CHAPTER 1 understanding of these factors might allow for possible barriers to the optimal implementation of this treatment to be identified.24–26 A study in the USA found that patients with first-­...

Differences between LAIs 76 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 ■ ■Adjust doses only after an adequate period of assessment Attainment of peak plasma levels, therapeutic effect and steady-­state plasma levels are all delayed with LAI a...

References Schizophrenia and related psychoses CHAPTER 1 References Tiihonen J, et al. Real-­world effectiveness of antipsychotic treatments in a nationwide cohort of 29823 patients with schizophrenia. JAMA Psychiatry 2017; 74:686–693. Kirson NY, et al. Effic...

Depot antipsychotics – summary of pharmacokinetics Schizophrenia and related psychoses CHAPTER 1 Depot antipsychotics – summary of pharmacokinetics Table 1.9 provides a summary of the pharmacokinetics of depot antipsychotic medications. Table 1.9  Depot antips...

References 82 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 References Mallikaarjun S, et al. Pharmacokinetics, tolerability and safety of aripiprazole once-­monthly in adult schizophrenia: an open-­label, parallel-­arm, multiple-­dose study. S...

Management of patients on long-term treatment with long-acting injectable antipsychotic medication Schizophrenia and related psychoses CHAPTER 1 Management of patients on long-­term treatment with long-­acting injectable antipsychotic medication For people wit...

References 84 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 ■ ■Discontinuation of medication should not be seen as the ultimate aim of the above process although it sometimes results. ■ ■Because of their longer half-­lives, relapse following dis...

Aripiprazole long-acting injection

Aripiprazole 1-monthly

One-injection start

Two-injection start Schizophrenia and related psychoses CHAPTER 1 Aripiprazole long-­acting injection Aripiprazole 1-­monthly Aripiprazole lacks the prolactin-­related and metabolic adverse effects of other SGA LAIs and so is a useful alternative to them. Plac...

Aripiprazole 2-monthly8,9 Schizophrenia and related psychoses CHAPTER 1 Aripiprazole 2-­monthly8,9 Two-­monthly ALAI (Aripiprazole 2-­Month Ready-­to-­Use 960mg [Ari2MRTU]) is ­indicated for maintenance treatment of schizophrenia (in the USA it is also license...

Other LAI aripiprazole brands 88 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 Other LAI aripiprazole brands Another two long-­acting formulations of aripiprazole lauroxil (Aristada Initio and Aristada) are approved by the US Food and Drug Admin...

References Schizophrenia and related psychoses CHAPTER 1 References Shirley M, et al. Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia. Drugs 2014; 74:1097–1110. US Food and Drug Administrati...